The approved oral medication Austedo (deutetrabenazine) or its extended-release formulation Austedo XR can help reduce the impact of Huntington’s disease-associated chorea, or involuntary movements, on patients’ daily activities and social interactions, while also easing the emotional and social burden on caregivers. Those are the findings of a U.S.